Interim estimates of the effectiveness of seasonal trivalent inactivated influenza vaccine in preventing influenza hospitalisations and primary care visits in Auckland, New Zealand, in 2014

SHIVERS Investigation Team

Interim estimates of the effectiveness of seasonal trivalent inactivated influenza vaccine in preventing influenza hospitalisations and primary care visits in Auckland, New Zealand, in 2014

SHIVERS Investigation Team

Institute of Tropical Medicine

Research output: Contribution to journal › A1: Web of Science-article › peer-review

Abstract

We present preliminary results of influenza vaccine effectiveness (VE) in New Zealand using a case test-negative design for 28 April to 31 August 2014. VE adjusted for age and time of admission among all ages against severe acute respiratory illness hospital presentation due to laboratory-confirmed influenza was 54% (95% CI: 19 to 74) and specifically against A(H1N1)pdm09 was 65% (95% CI:33 to 81). For influenza-confirmed primary care visits, VE was 67% (95% CI: 48 to 79) overall and 73% (95% CI: 50 to 85) against A(H1N1)pdm09.

Original language	English
Journal	Eurosurveillance
Volume	19
Issue number	42
ISSN	1560-7917
Publication status	Published - 2014

Keywords

Adolescent
Adult
Aged
Case-Control Studies
Child
Child, Preschool
Female
Hospitalization/statistics & numerical data
Humans
Infant
Influenza A Virus, H1N1 Subtype/genetics
Influenza Vaccines/administration & dosage
Influenza, Human/immunology
Male
Middle Aged
New Zealand
Primary Health Care/statistics & numerical data
Reverse Transcriptase Polymerase Chain Reaction
Seasons
Sentinel Surveillance
Young Adult

Cite this

@article{5c731b75809b48b593ac2ee2eb818dbd,

title = "Interim estimates of the effectiveness of seasonal trivalent inactivated influenza vaccine in preventing influenza hospitalisations and primary care visits in Auckland, New Zealand, in 2014",

abstract = "We present preliminary results of influenza vaccine effectiveness (VE) in New Zealand using a case test-negative design for 28 April to 31 August 2014. VE adjusted for age and time of admission among all ages against severe acute respiratory illness hospital presentation due to laboratory-confirmed influenza was 54% (95% CI: 19 to 74) and specifically against A(H1N1)pdm09 was 65% (95% CI:33 to 81). For influenza-confirmed primary care visits, VE was 67% (95% CI: 48 to 79) overall and 73% (95% CI: 50 to 85) against A(H1N1)pdm09.",

keywords = "Adolescent, Adult, Aged, Case-Control Studies, Child, Child, Preschool, Female, Hospitalization/statistics & numerical data, Humans, Infant, Influenza A Virus, H1N1 Subtype/genetics, Influenza Vaccines/administration & dosage, Influenza, Human/immunology, Male, Middle Aged, New Zealand, Primary Health Care/statistics & numerical data, Reverse Transcriptase Polymerase Chain Reaction, Seasons, Sentinel Surveillance, Young Adult",

author = "{SHIVERS Investigation Team} and N Turner and N Pierse and Huang, {Q S} and S Radke and A Bissielo and Thompson, {M G} and H Kelly and Marc-Alain Widdowson",

year = "2014",

language = "English",

volume = "19",

journal = "Eurosurveillance",

issn = "1560-7917",

publisher = "European Centre for Disease Prevention & Control",

number = "42",

}

TY - JOUR

T1 - Interim estimates of the effectiveness of seasonal trivalent inactivated influenza vaccine in preventing influenza hospitalisations and primary care visits in Auckland, New Zealand, in 2014

AU - SHIVERS Investigation Team

AU - Turner, N

AU - Pierse, N

AU - Huang, Q S

AU - Radke, S

AU - Bissielo, A

AU - Thompson, M G

AU - Kelly, H

AU - Widdowson, Marc-Alain

PY - 2014

Y1 - 2014

N2 - We present preliminary results of influenza vaccine effectiveness (VE) in New Zealand using a case test-negative design for 28 April to 31 August 2014. VE adjusted for age and time of admission among all ages against severe acute respiratory illness hospital presentation due to laboratory-confirmed influenza was 54% (95% CI: 19 to 74) and specifically against A(H1N1)pdm09 was 65% (95% CI:33 to 81). For influenza-confirmed primary care visits, VE was 67% (95% CI: 48 to 79) overall and 73% (95% CI: 50 to 85) against A(H1N1)pdm09.

AB - We present preliminary results of influenza vaccine effectiveness (VE) in New Zealand using a case test-negative design for 28 April to 31 August 2014. VE adjusted for age and time of admission among all ages against severe acute respiratory illness hospital presentation due to laboratory-confirmed influenza was 54% (95% CI: 19 to 74) and specifically against A(H1N1)pdm09 was 65% (95% CI:33 to 81). For influenza-confirmed primary care visits, VE was 67% (95% CI: 48 to 79) overall and 73% (95% CI: 50 to 85) against A(H1N1)pdm09.

KW - Adolescent

KW - Adult

KW - Aged

KW - Case-Control Studies

KW - Child

KW - Child, Preschool

KW - Female

KW - Hospitalization/statistics & numerical data

KW - Humans

KW - Infant

KW - Influenza A Virus, H1N1 Subtype/genetics

KW - Influenza Vaccines/administration & dosage

KW - Influenza, Human/immunology

KW - Male

KW - Middle Aged

KW - New Zealand

KW - Primary Health Care/statistics & numerical data

KW - Reverse Transcriptase Polymerase Chain Reaction

KW - Seasons

KW - Sentinel Surveillance

KW - Young Adult

M3 - A1: Web of Science-article

C2 - 25358042

SN - 1560-7917

VL - 19

JO - Eurosurveillance

JF - Eurosurveillance

IS - 42

ER -

Interim estimates of the effectiveness of seasonal trivalent inactivated influenza vaccine in preventing influenza hospitalisations and primary care visits in Auckland, New Zealand, in 2014

Abstract

Keywords

Fingerprint

Cite this